Skip to content

Author

Li-Li Yang

We have 3 of 60 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Adoptive MAIT cell therapy for liver cancer enhanced by multimodal modulation of immune receptors and checkpoints.

BACKGROUND Mucosal-associated invariant T (MAIT) cells are innate-like T lymphocytes that recognize riboflavin-derived metabolites presented by the monomorphic major histocompatibility complex (MHC)-class I-related molecule MR1. MAIT cells are highly enriched in the human liver and are increasingly implicated in liver...

Yan-Ruide Li, Xin-Yuan Shen, Yi-Chen Zhu et al. · 0 citations
Open access Aug 2026

Scalable generation of hematopoietic stem cell-engineered off-the-shelf mono-specific cytotoxic T cells targeting solid tumors

HSPC-derived AlloESO-T cells are established as an off-the-shelf, mono-specific cytotoxic T cell therapy with scalable manufacturing, enhanced efficacy, and improved safety, which support broad applicability of AlloESO-T cells across solid tumors.

Yi-Chen Zhu, Jia-Ji Yu, Y. J. Kim et al. · 0 citations
Review Open access Aug 2026

Emerging therapeutic opportunities targeting nonclassical MHC-I molecules.

The biology, disease-associated functions, and therapeutic targeting of nonclassical MHC-I molecules are synthesized, integrating immune checkpoint blockade, antibody-based therapeutics, and MR1- and CD1-restricted cellular immunotherapies into a unified framework.

Yan-Ruide Li, Yu-Ning Chen, Li-Li Yang · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.